Protalix BioTherapeutics Inc. PLX

ASE: PLX | ISIN: US74365A1016   17:52
1,700 USD (-0,58%)
(-0,58%)   17:52
Grafiek Protalix BioTherapeutics Inc. Grafiek Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc. in het nieuws

30 juni 2022 · Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors · Persbericht

26 mei 2022 · Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease · Persbericht

16 mei 2022 · Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results · Persbericht

9 mei 2022 · Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022 · Persbericht

4 april 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease · Persbericht

31 maart 2022 · Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results · Persbericht

24 maart 2022 · Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022 · Persbericht

18 maart 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease · Persbericht

27 februari 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease · Persbericht

3 februari 2022 · Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022 · Persbericht

Profiel Protalix BioTherapeutics Inc.

Diensten aan de gezondheidssector
Gezondheidszorg
Productie
Productie van biologische producten

CEO: Dror Bashan

Werknemers: 162

Aandelen Protalix BioTherapeutics Inc.

Beurswaarde: 122,40 miljoen USD

Effecten: 71,58 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,19

Mijn selecties